Chlorogen Secures Additional $6 Million In Venture Funding  
1/19/2006 10:46:48 AM

ST. LOUIS--(BUSINESS WIRE)--Jan. 19, 2006--Chlorogen, Inc., a venture-backed biopharmaceutical company focused on the development and manufacture of proteins for human therapy, has secured $6 million in additional venture funding. The company, which secured an initial $5.8 million in venture funding in 2003, will use the Series B investment to finance development of its lead product candidates, which include protein-based therapies for gynecological cancers. Four leading venture capital companies - Burrill & Co. of San Francisco, Harris & Harris Group of New York, Prolog Ventures of St. Louis, and Redmont Venture Partners of Birmingham, Ala.- funded the Series A investment. Finistere Partners LLC of San Diego joined these investors in the Series B funding.